For more than two decades, hormone replacement therapy (HRT) for menopause symptoms carried the FDA's strictest warning—a black box alert about increased breast cancer risk. But in 2025, the agency announced plans to remove some of those risk statements, and in 2026 it approved revised labeling for several hormone therapy products, according to Tufts Now.
The label changes addressed statements about cardiovascular disease, breast cancer, and probable dementia. However, the FDA did not eliminate all safety warnings or establish that hormone therapy carries zero cancer risk.
So what does this mean for the roughly 6,000 women in the United States who enter menopause each day? Tufts Now spoke with three doctors who treat women at various stages of menopause: Deborah Erlich, vice dean for academic affairs and professor of family medicine at Tufts University School of Medicine; Lucy Gade, an integrative gynecologist in New York; and Adrienne Mandelberger, also a gynecologist in New York.
How hormone therapy works
Erlich noted that many clinicians now prefer the term menopausal hormone therapy (MHT) over HRT, emphasizing that women are not deficient in hormones but rather are using medication to treat symptoms. The therapy involves estrogen and, for patients with a uterus, progesterone—the same hormones found in birth control pills but at much lower doses.
Estrogen helps with hot flashes, night sweats, and sleep issues, and may also improve bone density and possibly prevent cognitive decline. Progesterone protects the uterine lining. Patients who have had a hysterectomy can take estrogen alone.
Why the black box warning existed
In the early 2000s, a major study called the Women's Health Initiative (WHI) found that women taking combined estrogen-plus-progestin therapy had an increased risk of breast cancer, leading to the black box warning. The combined therapy part of the study was stopped early because the risks crossed a predefined boundary. The estrogen-only trial continued until 2004.
Gade explained that the WHI study had limitations. Participants were, on average, older and further into post-menopause than many women seeking treatment today. The study also used specific hormone formulations—oral conjugated equine estrogens and a synthetic progesterone—that differ from current options like transdermal estradiol and oral micronized progesterone.
Follow-up analyses in 2015 showed that breast cancer risks vary by hormone regimen, reinforcing the need for individualized treatment rather than applying risks from one formulation to all forms of therapy.
Timing matters
For otherwise healthy women with symptoms, the benefit-risk ratio is generally most favorable when treatment starts around the time of menopause or within 10 years after menopause, particularly before age 60, according to Gade. Starting after age 60 or more than 10 years after menopause requires more caution because cardiovascular and blood clot risks increase with age.
Gade noted that transdermal estrogen may carry a lower risk of venous thromboembolism than oral estrogen, based mainly on observational evidence.
Who is a good candidate?
Mandelberger said the ideal candidate is a symptomatic woman in early menopause. The strongest evidence supports hormone therapy for vasomotor symptoms like hot flashes, night sweats, and palpitations. FDA-approved uses also include treating symptoms of premature menopause (before age 40–45), genitourinary symptoms like vaginal dryness, and preventing osteoporosis.
Patients who have had hormone-dependent cancers, such as some breast and ovarian cancers, are not eligible for hormone therapy. Non-hormonal options are available for them.
Non-hormonal alternatives
In 2023, the FDA approved Veozah (fezolinetant), a nonhormonal medication that targets the brain's temperature control center to treat hot flashes and night sweats. Another drug, Lynkuet (elinzanetant), was approved in October 2025. Paroxetine, an SSRI used in higher doses as an antidepressant, is also FDA-approved for vasomotor symptoms.
Other medications, such as the antidepressant venlafaxine and the anti-seizure drug gabapentin, are sometimes used off label. Erlich cautioned patients about over-the-counter supplements, which are not FDA regulated and may contain caffeine or other stimulants. Eating soy products like edamame and tofu can help, as can regular exercise including cardiovascular activity, strength training, and flexibility work.
Gade recommended foods rich in fiber, micronutrients, and phytochemicals that support estrogen metabolism, such as cruciferous vegetables. Adequate intake of vitamins D and B12, magnesium, and omega-3 fatty acids also supports general health during midlife.
What this means for students
While menopause may seem distant for many university students, the conversation around hormone therapy affects millions of women—including family members, professors, and peers. Understanding the evolving science behind treatment options can help students make informed health decisions for themselves or support others navigating this stage of life.